Avecho and Chimeric both surged as traders chased near-term trial and funding catalysts, while Island Pharmaceuticals extended gains on a US biodefence partnership. Elsewhere, distribution and reimbursement wins supported smaller medtech names, and a cannabis merger plan kept Little Green Pharma in focus ahead of April’s vote.
- Avecho Biotechnology (ASX:AVE) jumped on progress toward interim Phase III data due in June 2026
- Chimeric Therapeutics (ASX:CHM) rallied after securing a $1.785m advance against its FY26 R&D tax incentive
- Island Pharmaceuticals (ASX:ILA) rose on a three-year USAMRIID agreement to speed Marburg drug work
- Little Green Pharma (ASX:LGP) pushed ahead with its Cannatrek scheme, with a 10 April 2026 meeting date set
- Reimbursement and distribution deals moved the commercial story along for Control Bionics (ASX:CBL), Rhythm Biosciences (ASX:RHY) and Osteopore (ASX:OSX)
Avecho Biotechnology (ASX:AVE) led the week with 33.33%, matched by Chimeric Therapeutics (ASX:CHM) at 33.33%. Island Pharmaceuticals (ASX:ILA) rounded out the biggest moves, climbing 13.51%. Investors largely bought these names for one reason: they each put a clearer date or dollar figure on what happens next.
Trial milestones: what matters and why prices moved
Avecho’s rise followed a simple update that traders treat as important. The company finished recruiting about 210 patients for the interim analysis group in its Phase III CBD insomnia trial. Phase III is a late-stage test that aims to show a medicine works and is safe in a larger group. The next clear event is the interim result, due June 2026. Investors cared because a positive interim look can make it easier to attract partners and keep funding the program. Island Pharmaceuticals gained after signing a CRADA research agreement with USAMRIID and the Geneva Foundation to advance Galidesivir for Marburg Virus Disease. In plain terms, it is teaming up with a major US biodefence lab to run key animal studies over three years, using a US FDA rule that can allow approval when human trials are not practical for dangerous viruses. The market liked the credibility and the clearer plan for what studies come next. Nexalis Therapeutics (ASX:NX1) also moved its science forward by starting a Phase 1 trial of an inhaled CBD product for panic disorder and recruiting its first participant. Phase 1 mainly checks safety and how the drug behaves in the body. It does not prove it works yet. Investors will likely wait for early safety and dosing results before pricing in Phase 2, which the company is aiming to start mid-2026.Funding and cash: small amounts still change the story
Chimeric’s spike came after it locked in a $1.785 million advance against its expected FY26 R&D Tax Incentive. This is not a new product sale. It is effectively bringing forward cash the company expects to receive later. Traders often like this because it can help pay for trials without an immediate share sale, even though it must be repaid by 31 December 2026 with interest. Entropy Neurodynamics (ASX:ENP) reported a $1.73 million R&D tax incentive refund tied to FY25 spending for its intravenous psilocin program. A refund is simpler than a loan: it is cash received, not cash borrowed. Even so, ENP fell -2.94%, which suggests investors still want to see clinical progress, not just funding updates. PYC Therapeutics (ASX:PYC) finished its retail entitlement offer, raising about $47 million at $1.50 a share, with new shares due to trade from 9 March 2026. The stock was down -0.33%. That mild move makes sense because a capital raise can cap the share price in the short term. Some buyers wait until the new shares hit the market.Market access and distribution: when “yes” matters more than “maybe”
Control Bionics (ASX:CBL) took a step that often changes sales outcomes in Europe. Its NeuroNode device became eligible for reimbursement under Germany’s statutory health insurance system. In everyday terms, more patients can get it paid for, which can remove a major barrier to adoption. The shares still slipped -1.67% for the week, which suggests investors want to see pricing and a distribution partner locked in next. Rhythm Biosciences (ASX:RHY) fell -13.95% despite signing a 12-month distribution deal with Digistain to launch geneType™ testing in Southeast Asia, starting in the Philippines. Distribution agreements can be valuable, but the market often waits for proof of orders and repeat sales. The deal is also non-exclusive, which gives flexibility but can look less certain than an exclusive partner. Osteopore (ASX:OSX) dropped -5.88% after securing a two-year, non-exclusive Singapore distribution deal for the Smart Dentin Grinder® dental graft technology. The product story is easy to grasp, turn extracted teeth into graft material quickly in the clinic, but revenue depends on local rollout, training, and steady clinic demand.Deal-making and regulatory calls: big outcomes, fixed dates
Little Green Pharma (ASX:LGP) added 4.76% as its planned acquisition of Cannatrek progressed, supported by an independent expert’s view that the scheme is fair and reasonable. The next hard catalyst is the scheme meeting on 10 April 2026, with implementation expected by 1 May 2026 if approved. Investors care because the deal aims to create a larger, vertically integrated medicinal cannabis group, but it still depends on shareholder votes and smooth integration. Neuren Pharmaceuticals (ASX:NEU) slid -5.36% after its partner, Acadia, said it would seek a re-examination of the European refusal to approve trofinetide for Rett syndrome. A re-examination is not a new trial result. It is a request for regulators to review the decision. Investors worry because the first decision cited limited treatment effect and study design issues, which are hard to “fix” quickly. Opthea Limited (ASX:OPT) was flat at 0.00% despite reporting a $339.9 million profit for H1 2026 linked to a settlement reversal and outlining a pivot toward developing OPT-302 for a rare lung disease (LAM). A profit driven by an accounting or legal outcome can be less important to biotech investors than future trial plans and timelines. Ansell Limited (ASX:ANN) fell -6.07% after confirming dividend details and a DRP price. Dividend administration rarely lifts a share price on its own, and the stock can still move with broader sentiment and currency settings because the dividend is paid in US dollars.Bottom Line?
Next week’s near-term focus is PYC Therapeutics (ASX:PYC) as new entitlement shares are scheduled to begin trading on 9 March 2026. The next major set-piece event on the calendar is Little Green Pharma’s (ASX:LGP) scheme meeting on 10 April 2026, while Avecho (ASX:AVE) has flagged June 2026 for interim Phase III results that could reset expectations either way.
Questions in the middle?
- Avecho Biotechnology (ASX:AVE): Will the June 2026 interim analysis be strong enough to support an over-the-counter approval plan, or will it force a trial redesign?
- Little Green Pharma (ASX:LGP): Can shareholders agree on the mix of ordinary shares and convertible preference shares, and will the merger still pencil out if pricing pressure continues?
- Neuren Pharmaceuticals (ASX:NEU): What new arguments can Acadia bring in the EU re-examination that directly address the regulator’s concerns about effect size and study design?